Survival statistics according to the staging schemas
| Stage | 2009 FIGO schema | 2021 FIGO schema | ||||||
| Overall survival | Cancer mortality* | Overall survival | Cancer mortality* | |||||
| 5 year (%) | Median (month) | 5 year (%) | Median (month) | 5 year (%) | Median (month) | 5 year (%) | Median (month) | |
| IIIA | 48.9 (42.9–54.7) | 51 (42–77) | 34.0 (28.4–39.7) | —† | 45.6 (38.5–52.5) | 43 (36–70) | 37.5 (30.6–44.3) | —† |
| IIIB | 44.2 (34.5–53.4) | 50 (26–77) | 38.3 (29.2–47.4) | —† | 47.0 (40.6–53.2) | 51 (39–74) | 35.5 (29.6–41.5) | —† |
| IIIC | 30.3 (22.8–38.1) | 18 (14–23) | 53.3 (44.6–61.2) | 39 (22–na) | 30.3 (22.8–38.1) | 18 (14–23) | 53.3 (44.6–61.2) | 39 (22–na) |
| IVA | 25.1 (18.1–32.8) | 18 (13–22) | 52.4 (43.6–60.5) | 39 (20–na) | 13.9 (7.1–22.9) | 11 (8–18) | 60.3 (48.0–70.5) | 20 (12–na) |
| IVB | 14.5 (9.7–20.3) | 7 (5–11) | 64.3 (56.9–70.8) | 12 (8–18) | 14.5 (9.7–20.3) | 7 (5–11) | 64.3 (56.9–70.8) | 12 (8–18) |
The 5 year overall survival or cumulative vulvar cancer mortality rates are shown according to the 2009 or 2021 FIGO staging schemas. Ranges indicate 95% confidence interval.
*Cumulative vulvar cancer mortality accounted for other causes of death.
†Not reached.
FIGO, International Federation of Gynecology and Obstetrics; na, not applicable.